Expand all sections

Lonafarnib

Zokinvy

Extended indication Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically con
Therapeutic value No estimate possible yet
Registration phase Positive CHMP opinion

Product

Active substance Lonafarnib
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Metabolic diseases
Extended indication Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
Proprietary name Zokinvy
Manufacturer Eiger Bio
Mechanism of action Other, see general comments
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Protein farnesyltransferase inhibitor

Registration

Registration route Centralised (EMA)
Type of trajectory Accelerated assessment
Submission date April 2020
Expected Registration July 2022
Orphan drug Yes
Registration phase Positive CHMP opinion
Additional remarks Positieve CHMP opinie ontvangen in mei 2022.

Therapeutic value

Current treatment options Uitsluitend symptoombehandeling
Therapeutic value No estimate possible yet
Frequency of administration 2 times a day
Dosage per administration 150 mg/m2
References NCT02579044; Leslie B. et al.Association of Lonafarnib Treatment versus No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome;

Expected patient volume per year

Patient volume

> 1

Market share is generally not included unless otherwise stated.
References orpha.net
Additional remarks Hutchinson-Gilford Progeria is zeer zeldzaam, de prevalentie ligt lager dan 1 op de 1.000.000. Er is op dit moment één patiënt bekend in Nederland.

Expected cost per patient per year

References https://endpts.com/eiger-nabs-an-fda-approval-for-progeria-an-ultra-rare-premature-aging-disease-after-merck-gave-them-the-drug-for-free/
Additional remarks De prijs zal in dezelfde range liggen als andere ultraweesgeneesmiddelen en dus aanzienlijk zijn.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
References adisinsight
Additional remarks Geen indicatie-uitbreidingen buiten de indicaties in de Horizonscan Geneesmiddelen.

Other information

There is currently no futher information available.